- |||||||||| Halaven (eribulin mesylate) / Eisai
Evaluation of eribulin-induced alterations of the intact immune cell landscape in spleens and tumors from tumor-bearing immunocompetent mice (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_252; Evaluation of immune cell components in the associated fixed tumors from eribulin- and vehicle-treated mice is currently ongoing to assess what effect, if any, such changes in the spleen will have on the tumor immune microenvironment; these results will be presented at the meeting. In conclusion, our results point to significant and unexpected effects of eribulin treatment on the immune cell landscape in spleens and tumors from tumor-bearing immunocompetent mice.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: Treatment of advanced soft tissue sarcoma by histological subtype: wish, prediction or reality? (Pubmed Central) - May 15, 2020 Options for second and later lines include ifosfamide, trabectedin, pazopanib, eribulin and gemcitabine-based regimens...Fortunately, the sarcoma community shares the common goal of seeking greater knowledge about the characteristics of each subtype in order to improve diagnosis and outcomes. Progress made to date in this regard suggests that the vision to treat by subtype is achievable.
- |||||||||| Halaven (eribulin mesylate) / Eisai, Turalio (pexidartinib) / Daiichi Sankyo
Trial completion, Trial completion date, Metastases: Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer (clinicaltrials.gov) - May 14, 2020 P1/2, N=67, Completed, Progress made to date in this regard suggests that the vision to treat by subtype is achievable. Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Jul 2019
- |||||||||| Halaven (eribulin mesylate) / Eisai
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: ERIBRAIN: Eribulin in Brain Metastases From HER2-negative Breast Cancer (clinicaltrials.gov) - May 6, 2020 P2, N=0, Withdrawn, Trial completion date: Jun 2022 --> May 2023 | Trial primary completion date: Jun 2022 --> May 2023 N=95 --> 0 | Trial completion date: Mar 2024 --> Apr 2020 | Recruiting --> Withdrawn | Trial primary completion date: Mar 2024 --> Apr 2020
- |||||||||| Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma
[VIRTUAL] The potential role of extracellular matrix in the activity of trabectedin. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_5878; Moreover these results shed the light on the potential role of ECM in the mechanism of action of trabectedin in L-sarcomas. The work points out the role of this tumor microenvironment component in predicting response to trabectedin and provide the rationale for better stratifying patients which will be candidate for this drug.
- |||||||||| thalidomide / Generic mfg., Halaven (eribulin mesylate) / Eisai
Biomarker, Review, Journal: Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: From pathogenesis to treatment. (Pubmed Central) - Apr 23, 2020 Currently, there is no established therapy for CIPN prevention or treatment; symptomatic treatment for neuropathic pain and dose reduction or withdrawal in severe cases is considered, at the cost of reduced cancer therapeutic efficacy. This review critically examines the pathogenesis, epidemiology, risk factors (both clinical and pharmacogenetic), clinical phenotype and management of CIPN as a result of exposure to vinca alkaloids, thalidomide and its analogue lenalidomide as also eribulin.
- |||||||||| Halaven (eribulin mesylate) / Eisai
Clinical, Journal: A Case of Advanced Breast Cancer with Altered Biology by Eribulin Chemotherapy (Pubmed Central) - Apr 23, 2020 Subsequent treatment with eribulin was started, and partial response was obtained; however, new lymph node metastasis developed in the axilla after 11 cycles. The primary tumor and axillaryly mph nodes showed stronglypositive ER expression, were PgR-negative and HER2-positive, and showed Ki-67 low expression and HER2-positive conversion.
- |||||||||| Halaven (eribulin mesylate) / Eisai
Clinical, Journal, Circulating Tumor Cells: 53BP1 Accumulation in Circulating Tumor Cells Identifies Chemotherapy-Responsive Metastatic Breast Cancer Patients. (Pubmed Central) - Apr 15, 2020 Here, we prospectively monitored the 53BP1 status in CTCs from 67 metastatic breast cancer (MBC) patients with HER2- CTCs and known hormone receptor (HR) status of the primary tumor and/or metastases before, during, and at the end of chemotherapeutic treatment with Eribulin...Kaplan-Meier analysis revealed an increasing association between nuclear 53BP1-positivity and progression-free survival (PFS) during chemotherapy until the final visit. Our data suggest that 53BP1 detection in CTCs could be a useful marker to capture dynamic changes of chemotherapeutic responsiveness in triple-negative and HR+ MBC.
- |||||||||| Halaven (eribulin mesylate) / Eisai
Journal: Eribulin-Associated Foot Drop. (Pubmed Central) - Apr 10, 2020 Our data suggest that 53BP1 detection in CTCs could be a useful marker to capture dynamic changes of chemotherapeutic responsiveness in triple-negative and HR+ MBC. No abstract available
- |||||||||| paclitaxel trevatide (ANG1005) / Angiochem
Trial completion date, Trial primary completion date: ANGLeD: ANG1005 in Leptomeningeal Disease From Breast Cancer (clinicaltrials.gov) - Apr 2, 2020 P3, N=150, Not yet recruiting, Completed --> Active, not recruiting | Trial completion date: Jul 2015 --> Mar 2020 Trial completion date: Jul 2022 --> Dec 2022 | Trial primary completion date: Oct 2021 --> Mar 2022
- |||||||||| AiTan (rivoceranib) / HLB Bio Group, Halaven (eribulin mesylate) / Eisai, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: Immuno2020-01: A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC (clinicaltrials.gov) - Apr 1, 2020 P2, N=46, Recruiting, Trial completion date: Jul 2022 --> Dec 2022 | Trial primary completion date: Oct 2021 --> Mar 2022 Not yet recruiting --> Recruiting
|